Cell Cover: Atlas of Human Cellular Senescence Unveiled, Ushering in the Era of Precision Anti-Aging
Release time:
2026-06-22
On June 11, 2026, the top international academic journal Cell published a landmark study as its cover article, led by the Cellular Senescence Network (SenNet) consortium of the U.S. National Institutes of Health (NIH): Charting Human Cellular Senescence in Aging and Disease. Directed by Professor Rong Fan’s team at Yale University, this research produced the world’s first systematic, high-resolution atlas of human cellular senescence, marking a pivotal shift from vague to precise understanding of aging.
The Enigma of Aging: More Than Just “Arrested Division”
Cellular senescence was first observed in vitro—cells remain metabolically active even after division ceases. Subsequent studies confirmed that this phenomenon also occurs in the human body. Senescent cells not only lose proliferative capacity but also secrete large amounts of pro-inflammatory factors (the SASP), remodeling the surrounding microenvironment and thereby driving tissue functional decline and chronic disease progression. Over the past decades, scientists have primarily identified senescence markers (e.g., p16, p21) through animal models and in vitro experiments, but knowledge of the true distribution, heterogeneity, and functional impact of senescent cells in humans has remained extremely limited.
Charting the Blueprint: A “Senescence Map” of the Human Body
To address this gap, the SenNet consortium integrated single‑cell sequencing, spatial multi‑omics, and AI‑based analytical technologies to construct the first reference atlas of human senescent cells across the entire lifespan, multiple tissues, and diverse disease states. Currently, publicly available data cover 17 tissues, including lymph nodes, lung, and prefrontal cortex, with parallel publications in Cell, Nature, and Cell Press journals. The cover image vividly illustrates the process: within an hourglass, initially vibrant cells gradually transform into states marked by chromatin disorganization, mitochondrial dysfunction, and aberrant morphology—symbolizing the consortium’s systematic tracking of senescent dynamics.
Key Findings: Senescence Is Not a “Single State”
The study introduces the concept of “senotypes,” emphasizing the high heterogeneity of senescent cells:
-
Normal aging: For example, Sloan et al. reported in Cell Genomics that the human prefrontal cortex exhibits layer‑ and cell‑type‑specific senescence programs, with astrocytes and endothelial cells in white matter and cortical layer I being particularly prominent.
-
Immunosenescence: Farzad et al. generated a lymph node atlas showing that germinal center B cells progressively accumulate senescent features with age, explaining the age‑related decline in immune function.
-
Disease‑associated senescence: Karpova’s team identified multiple distinct senescent cell populations (e.g., CDKN1A+ hepatocytes, CXCL12+ fibroblasts) in liver fibrosis and colorectal cancer liver metastases, suggesting their potential as therapeutic targets.
-
Chronic wounds: Wyles et al. found that p16+ senescent cells enriched in chronic wounds are closely associated with matrix remodeling and immune cell aggregation, revealing a key pathological mechanism of non‑healing wounds.
From Atlas to Clinic
The SenNet consortium further constructed the multi‑omic Senescence Catalog (SenCat) and trained a new‑generation machine‑learning model capable of accurately identifying distinct senescent cell types. In two large population cohorts—the Baltimore Longitudinal Study of Aging and the Italian InCHIANTI study—researchers validated circulating senescence markers:
-
Renal epithelial cell senescence → strongest predictor of kidney disease;
-
Immune cell senescence → significantly associated with diabetes, frailty, and future mortality risk.
On the therapeutic front, the consortium identified novel senolytics, such as α‑eleostearic acid and its methyl ester, which can induce ferroptosis in senescent cells via the ACSL4‑LPCAT3‑ALOX15 pathway, thereby extending healthspan in mice.
Future Outlook
Professor Rong Fan, Executive Director of the SenNet consortium, remarked: “This atlas allows us, for the first time, to see the true distribution and diversity of senescent cells within the human body.” The consortium has made all data openly accessible at https://data.sennetconsortium.org for researchers worldwide. Industry experts believe this achievement will shift the medical paradigm from “treating disease after onset” to “pre‑identifying and eliminating harmful senescent cells,” with promising breakthroughs expected in neurodegenerative diseases, fibrotic liver disease, chronic wounds, and metabolic syndrome.
Latest developments
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
